I-Mab, a clinical stage biopharmaceutical company based in China, has entered into a strategic collaboration with Roche Diagnostics to co-develop companion diagnostics (CDx) solutions for I-Mab's innovative pipeline.

Companion diagnostics have become an important part of the innovative biologics R&D process. They are used to detect expression levels of proteins and mutated genes, and to help identify the right candidates among patients with different types of diseases.

Using companion diagnostics can help innovative biotech companies improve R&D efficiency, ensure the effectiveness and safety of drugs, and control R&D costs.

Under this collaboration, I-Mab and Roche Diagnostics will jointly develop companion diagnostics solutions for the innovative assets under development by I-Mab to accelerate the research and development process of innovative biologics with cutting-edge diagnosis and treatment technologies.

"This collaboration further strengthens our R&D capabilities, marking yet another milestone on our journey to transform into a fully integrated global biopharmaceutical company," said Dr. Joan Shen, Chief Executive Officer of I-Mab.